Cannabis Rescheduling: What We Know, What’s Rumor, And What To Watch Next

Reports across major outlets say President Donald Trump is expected to address marijuana rescheduling as soon as Thursday, with some reporting describing a potential executive action aimed at moving cannabis from Schedule I to Schedule III. A White House official said any details about potential action should be treated as speculation until the White House officially announces it.

That ambiguity is exactly why the industry is in limbo. Operators, investors and policymakers are attempting to prepare for a potentially historic shift without a signed document, a clear mechanism or an effective date.

Here’s what we know, what we don’t know yet and what decision-makers should be watching.

What’s confirmed vs. what’s not

Confirmed

Multiple outlets report that Trump is expected to address marijuana rescheduling this week.
Trump has publicly said he is considering reclassification, framing it as a way to expand medical research that is currently constrained under federal law.
A federal rescheduling framework already exists under the Controlled Substances Act, meaning any change must ultimately be implemented through executive or agency action.

Not confirmed (yet)

Whether Trump will sign an executive order or issue another form of directive.
Whether any action would attempt to change scheduling immediately or instead instruct agencies to move faster.
Whether Schedule III is the final target or one of several options under consideration.
When any change, if announced, would actually take effect.

What rescheduling to Schedule III would actually mean

If marijuana is moved to Schedule III, it would no longer sit in the most restrictive federal category reserved for substances deemed to have no accepted medical use. Schedule III substances are recognized under federal law as having medical use, while remaining controlled and regulated.

The key point: rescheduling is a regulatory reclassification, not a legalization switch. Even under Schedule III, cannabis would remain a controlled substance under federal law.

The biggest near-term business question: 280E

If marijuana becomes a Schedule III substance, a central industry focus will be whether and when that change neutralizes IRS Code Section 280E. The provision currently prevents businesses trafficking Schedule I or II substances from taking standard tax deductions.

That’s why “Schedule III” has become a market-moving phrase. But the real-world tax impact still hinges on timing, implementation and how federal agencies interpret and apply the change.

What rescheduling would not do

Even in the most favorable Schedule III scenario, several structural constraints would remain:

No federal legalization: Rescheduling would not legalize adult-use cannabis nationwide or eliminate the federal-state conflict.
No automatic banking fix: Major banking, capital-markets and interstate commerce barriers would still require separate legislative or regulatory action.
No immediate clarity on workplace drug testing: Employers, federal contractors and safety-sensitive industries are unlikely to see rapid rule changes without targeted agency guidance.

Why the “how” matters more than the headline

Even if the president announces a rescheduling move, the practical impact depends on how it is executed. Scheduling changes are not self-executing, and implementation details determine what changes on paper versus what changes in practice.

That’s why the industry is watching for the specific mechanism:

Does a presidential action direct agencies to act on a defined timeline?
Does it attempt to change scheduling outright, or frame the move as an accelerated review?
Does it address enforcement posture, interagency coordination or regulatory priorities?

Until a primary document is released, it remains difficult to assess the real-world implications.

What to watch for next

For operators, investors and policymakers, these are the signals that matter most:

The primary document (executive order, directive, memo or transcript)
The stated target (explicit Schedule III language versus broader review framing)
Any effective date or milestones
Agency roles (DEA, DOJ, HHS and whether FDA posture is referenced)
Enforcement signals, if any
Legal exposure, including language that could invite or deter court challenges.

Bottom line

Rescheduling may represent the biggest federal cannabis policy shift in decades, but it is still not legalization and it is not automatic. Markets will react to headlines. The industry will live with implementation.

IgniteIt will update this explainer as soon as official documentation is released and agency timelines become clear.